摘要 |
The present invention relates to the field of medicine, pharmaceutics, nano-technology and colloidal chemistry, in particular to a method for producing a water-soluble medicinal form (pharmaceutical composition) of an antibiotic from the group consisting of rifamycins, such as rifabutin, rifampicin, rifapentin, rifaximin and the pharmaceutically acceptable derivatives thereof for the treatment of tuberculosis. The problem addressed by the claimed solution is to simplify the technology for producing a pharmaceutical composition of the antibiotic from the group consisting of rifamycins, and also to eliminate highly toxic chloroorganic solvents. The claimed technical solution is directed towards producing a pharmaceutical composition of the antibiotic from the group consisting of rifamycins suitable for parenteral (intravenous) administration to a patient requiring treatment. The above-mentioned composition is produced by a method comprising a) dissolving the antibiotic from the group consisting of rifamycins in an organic solvent selected from a group consisting of solvents which mix with water; b) adding an aqueous solution of albumin produced by dissolving albumin in a 1-10% molar ratio in sterilized demineralized water to the solution produced in step a); c) stirring the mixture produced; d) filtering said mixture; e) adding a cryoprotector; f) freezing said mixture; g) drying said mixture (lyophilically or by spray drying). |